Drugs / Panagen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02115984 | May 2010 → May 2012 | breast cancer | Panagen, Limited Liability Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Panagen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02115984 ↗ |
| Action | Activate | “Panagen acts by activating dendritic cells and induces the development of adaptive anticancer immune response.” PMID 27538465 ↗ Aug 2016 |
| Modality | Other / unclassified | “human dsDNA-based preparation Panagen in a tablet form” PMID 25886605 ↗ Mar 2015 |
| Route | Oral | “Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days.” NCT02115984 ↗ |